| Entries |
| Document | Title | Date |
|---|
| 20080213279 | Blocking Leukocyte Emigration and Inflammation By Interfering With Cd99l2 - The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that the adhesion molecule CD99L2 mediates TEM of leukocytes. CD99L2 is present on endothelial cells and leukocytes and mediates leukocyte-endothelial cell adhesion. Blockade of CD99L2 by use of a specific antibody blocks migration of leukocytes into a site of inflammation. CD99L2 shows functional analogy to the structurally-related molecule, CD99, inhibition of which, in conjunction with inhibition of PECAM, causes near total blockade of TEM. Thus, blocking CD99L2 on either endothelial cells or monocytes can block migration 80-90%. In conjunction with PECAM inhibitors, TEM blockade can approach 100%. Therapeutic treatments involving inhibition of CD99L2 show significant promise in remediation of inflammatory conditions. | 09-04-2008 |
| 20080213280 | THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR - The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor. | 09-04-2008 |
| 20080226653 | Inhibition of Platelet Aggregation - The present invention relates generally to the field of hyperglycemia-induced complications. More particularly, it concerns methods and compositions for the treatment and prevention of microvascular complications associated with diabetes. In one embodiment, the present invention provides a method of inhibiting hyperglycemia-induced platelet activation in a subject by administering to the subject an effective amount of a TRPC6 inhibitor. | 09-18-2008 |
| 20080254037 | METHOD OF TREATING ISCHEMIA REPERFUSION INJURY BY INHIBING NKT CELL ACTIVITY - The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A | 10-16-2008 |
| 20080267972 | Donor Lymphocyte Infusion of T Cells For the Treatment of Cancer - The present invention relates generally to the treatment of cancer using donor lymphocyte infusions of T cells. Further, the present invention relates generally to methods for stimulating and activating allogeneic and/or xenogeneic cells which can then be used in a DLI setting. | 10-30-2008 |
| 20090010940 | Parathyroid Hormone Analogues and Methods of Use - The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects. | 01-08-2009 |
| 20090017039 | SP35 Antibodies and uses thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody | 01-15-2009 |
| 20090017040 | Monoclonal antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD) | 01-15-2009 |
| 20090017041 | Monoclonal antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 01-15-2009 |
| 20090060921 | GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES - Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided. | 03-05-2009 |
| 20090074788 | Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved - The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method. | 03-19-2009 |
| 20090098140 | MONOCLONAL ANTIBODIES AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. These antibodies are of use to detect and isolate pancreatic cells or a subset thereof. The antibodies can be used for in vitro or in vivo detection and/or isolation of pancreatic endocrine cells. Methods of treating a pancreatic tumor are also disclosed. In several examples, the isolated monoclonal antibodies bind pancreatic endocrine cells and can be used to detect diabetes or a pancreatic endocrine cell tumor. | 04-16-2009 |
| 20090142355 | DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES - Methods for the diagnosis and treatment of type 1 diabetes are described. HLA-DQA2 has now been identified as the gene which is primarily responsible for determining whether an individual is susceptible to develop type 1 diabetes. The use of HLA-DQA2 as a target for developing therapeutic and diagnostic targets for treating type 1 diabetes and detecting susceptibility for the disease is disclosed. | 06-04-2009 |
| 20090148460 | EXOSOME LIGANDS, THEIR PREPARATION AND USES - The present invention relates to exosome-specific ligands and compositions comprising the same. The invention also relates to methods of generating said ligands and compositions, to methods of using said ligands or compositions, e.g., to block the exosome pathway or to detect and/or characterize exosomes in a sample or subject, as well as to the antigens contacted by said ligands or compositions. The application can be used in experimental, research, therapeutic, prophylactic or diagnostic areas. | 06-11-2009 |
| 20090148461 | ANTI FGF23 ANTIBODY AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772). | 06-11-2009 |
| 20090169565 | NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody. | 07-02-2009 |
| 20090196875 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 08-06-2009 |
| 20090220523 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY AND NEOVASCULARIZATION CONDITIONS - The present invention relates to compositions and methods for the treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of the bioactive lipids. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphinxine-1-phosphate (S1P) or lysophosphophatidic acid (LPA). | 09-03-2009 |
| 20090285828 | Anti-PECAM Therapy for Metastasis Suppression - The invention provides novel compositions, methods, kits, and uses thereof relating to antimetastatic agents useful for treating neoplastic diseases. | 11-19-2009 |
| 20090285829 | Medicinal Agent and Method for Curing Prostate Diseases - A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to homeopathic technology. In order to obtain the antibodies, the prostate-specific antigen isolated from the prostatic tissues of cattle or prepared synthetically is employed; a mixture of various, mostly centesimal, homeopathic dilutions is used. The method of treating diseases of the urogenital sphere consists in using activated forms of ultra-low doses of antibodies to prostate-specific antigen prepared by multiple consecutive dilutions and exposure to external factors. | 11-19-2009 |
| 20100008931 | Coronin 1 Modulators for the Treatment of Autoimmune and Lymphoproliferative Disorders and Mycobacterial Infections - The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a coronin 1 precursor, partly or entirely inactivate coronin 1, inhibit concentration of coronin 1 at the site of T cell activation, or inhibit the coronin 1 mediated signaling pathway downstream of the T cell receptor Examples of such modulators are antibody or antibody fragments, coronin 1 peptide fragments or corresponding phosphopeptides, or anti-sense oligonucleotides, e.g. siRNA or shRNA. The invention further relates to a method of screening for a compound effective in the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation comprising contacting a candidate compound with coronin 1 or coronin 1 expressing cells, and selecting appropriate compounds. | 01-14-2010 |
| 20100074904 | SPECIFIC ACTIVATION OF A REGULATORY T CELL AND ITS USE FOR TREATMENT OF ASTHMA, ALLERGIC DISEASE, AUTOIMMUNE DISEASE, GRAFT REJECTION AND FOR TOLERANCE INDUCTION - The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction. | 03-25-2010 |
| 20100080811 | ANTI-MYOSTATIN ANTIBODIES - Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species. | 04-01-2010 |
| 20100129376 | Osteopontin Specific Antibodies and Methods of Use Thereof - Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders. | 05-27-2010 |
| 20100172913 | FIBROSIS INHIBITOR - An objective of the present invention is to provide methods for treating or preventing fibrotic diseases, which are based on the novel finding that fibrosis is suppressed by administering ER-TR7 to a subject. | 07-08-2010 |
| 20100196392 | ANTI-SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof. | 08-05-2010 |
| 20100196393 | MODULATION OF BLOOD BRAIN BARRIER PROTEIN EXPRESSION - There are disclosed agents that inhibit Blood Brain Barrier Proteins (BBBP). Such agents are useful in controlling agents entering and exiting the CNS. This allows for drugs to be more effective and/or allowing side effects of the drugs to be lowered. | 08-05-2010 |
| 20100226927 | SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT - The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance. | 09-09-2010 |
| 20100226928 | Lyophilised Antibody Formulation - Anti-sclerostin antibodies are formulated as lyophilisates. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 25 mg/ml. The lyophilisate may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid. | 09-09-2010 |
| 20100239591 | MONOCLONAL ANTIBODY FOR APP - The invention relates to a novel peptide, polypeptide or monoclonal antibody for use in the treatment of conditions characterised by elevated levels of β-amyloid (Aβ 39-43 amino acid peptide) in a subject, especially Alzheimer's Disease. The invention particularly relates to an amyloid precursor protein (APP)-binding polypeptide which, when administered outside an APP-expressing cell, reduces the release of Aβ 39-43 by the cell. | 09-23-2010 |
| 20100278836 | DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASE - Low levels of antibodies reactive with a PAF-conjugate are related to an increased risk of developing cardiovascular diseases. Thus, compositions and methods of diagnosis and therapy for cardiovascular diseases are provided. | 11-04-2010 |
| 20100291101 | NEW ANTI-IRC85 MONOCLONAL ANTIBODY; AND COMPOSITION COMPRISING THE SAME FOR PREVENTING AND TREATING TUBERCULOSIS OR ENTERITIS DISEASE; AND THE USE THEREOF - The present invention provides the novel anti-IRC85 monoclonal antibody specifically binding with IRC85 and it showed potent effect in removing the infected/phagocytosed bacteria from THP-I, a monocytic cell that expresses human IRC85 and is infected with | 11-18-2010 |
| 20100303824 | SIGNALING INTERMEDIATES IN AN IN VITRO MODEL OF ALZHEIMER'S DISEASE - The invention provides a novel human protein, FISH adaptor protein, involved in amyloid β-protein-mediated cell death. Also provided are methods for modulating amyloid β-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein. | 12-02-2010 |
| 20100322945 | IMMUNOGENIC COMPOUNDS AND PROTEIN MIMICS - The invention provides means and methods for inducing and/or enhancing immunogenic reproducibility and/or immunogenicity of a compound, comprising at least in part restricting the conformation of said compound. The conformation is preferably restricted by the formation of at least one internal bond within said compound. Protein mimics comprising an amino acid sequence bound to a scaffold and/or a carrier, wherein said amino acid sequence comprises at least one internal SS-bridge, are also herewith provided. | 12-23-2010 |
| 20110033477 | METHOD FOR DIAGNOSING AND TREATING CHRONIC PSYCHIATRIC ILLNESSES AND MARKERS AND TARGETS FOR SUCH METHODS - The invention relates to the use of special conformers of the DISC1 protein as a marker or target for chronic psychiatric illnesses, particularly schizophrenia, bipolar disorder, or depression. | 02-10-2011 |
| 20110038875 | HEMATOPOIETIC CELLS EXPRESSING THE PROTEIN SUSD3 AND LIGANDS FOR THE PROTEIN SUSD3 - The present invention relates to ex vivo hematopoietic cells characterized by the expression of the protein SUSD3 on the surface of said cells, to methods for preparing said cells and to ligands for SUSD3. | 02-17-2011 |
| 20110081354 | ANTI-CTLA-4 ANTIBODIES WITH REDUCED BLOCKING OF BINDING OF CTLA-4 TO B7 AND USES THEREOF - The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention. | 04-07-2011 |
| 20110091473 | NOVEL ANTIBODY THERAPIES - Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has a beneficial effect on said disease or disorder or (ii) for use in the treatment of such disease or disorder, wherein the antibody is to be administered to a subject undergoing therapy with a cholesterol-lowering agent, such as a statin, and wherein the subject is withdrawn from treatment with the cholesterol-lowering agent prior to the administration of the antibody. Furthermore, a kit of parts comprising such antibody as well as a cholesterol-increasing agent. | 04-21-2011 |
| 20110104176 | ANTIBODY SPECIFICALLY BINDING TO C-MET AND USE THEREOF - Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed. | 05-05-2011 |
| 20110135653 | Antibodies Against HER2 Truncated Variant CTF-611 - The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. | 06-09-2011 |
| 20110165168 | CIDEA MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CIDEA protein, and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 07-07-2011 |
| 20110165169 | COMPLEMENT INHIBITORS AND USES THEREOF - The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 07-07-2011 |
| 20110182908 | Diagnostics and Therapeutics for Macular Degeneration-Related Disorders - The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders. | 07-28-2011 |
| 20110200609 | MONOCLONAL ANTIBODIES SPECIFIC FOR PATHOLOGICAL AMYLOID AGGREGATES COMMON TO AMYLOIDS FORMED FROM PROTEINS OF DIFFERING SEQUENCE - Monoclonal antibody compositions, methods of production and use. The monoclonal antibodies are specific to conformational epitope(s) of a prefibrillar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g., Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. The monoclonal antibodies are useable for immunization of human or animal subjects against Alzheimer's Disease or other amyloid diseases and/or for the diagnosis or detection of Alzheimer's Disease or other amyloid diseases. The monoclonal antibodies may be administered concomitantly or in combination with anti-inflammatory agents, such as gold or gold containing compounds, to decrease neural inflammation associated with amyloid diseases (e.g., Alzheimer's Disease). | 08-18-2011 |
| 20110243952 | COMPOUND AND METHOD FOR REGULATING PLASMINOGEN ACTIVATION AND CELL MIGRATION - The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof. | 10-06-2011 |
| 20110250208 | Oxidized Cardiolipin as a Novel Pro-Inflammatory Factor - Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided. | 10-13-2011 |
| 20110268742 | PCTP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 11-03-2011 |
| 20110287019 | THERAPEUTIC TARGETING OF ESCORT PROTEINS - The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein like Tsg101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse. | 11-24-2011 |
| 20110300152 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - Compositions and methods are provided for modulating cell-cell fusion by using agents that modulate expression, activity, or function of intermediate-conductance calcium-activated potassium (SK4) channel. In some embodiments, the compositions and methods of the invention provide for inhibition of multi-nucleated osteoclastogenesis and cell-cell fusion, especially cell fusion involving macrophages. In such embodiments, the compositions can comprise inhibitory nucleic acids, monoclonal antibodies or small molecule inhibitors of the SK4 channels and find use in preventing and/or treating various diseases or disorders including bone loss, autoimmune and inflammatory diseases or disorders, implant and transplant rejection, and cancer metastasis. In other embodiments, the compositions and methods of the invention provide for activation of cell-cell fusion. Also provided are methods to screen for SK4 channel modulators (inhibitors or activators) that modulate cell-cell fusion, particularly macrophage cell fusion. | 12-08-2011 |
| 20110305707 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention provides methods for treating cancer in a subject, as well as related compositions and kits that employ a therapeutic agent, or a nucleic acid sequence encoding a therapeutic agent, selected from apolipoprotein A-1 (ApoA1) or biologically active fragment, an ApoA1 mimetic, an agent that increases expression of ApoA1, or a binding agent specific for oxidized ApoA1. In certain embodiments, the ApoA1 or ApoA1 mimetic is at least partially oxidation resistant. | 12-15-2011 |
| 20120003231 | CELL SURFACE MOLECULE MEDIATING CELL ADHESION AND SIGNAL TRANSMISSION - Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases. | 01-05-2012 |
| 20120009197 | Anti-Human Equilibrative Nucleoside Transporter 1 (hENT1) Antibodies and Methods of Use Thereof - This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity. | 01-12-2012 |
| 20120014962 | METHOD OF INHIBITING FIBROGENESIS AND TREATING FIBROTIC DISEASE - The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and/or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention. | 01-19-2012 |
| 20120039904 | ANTI SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof. | 02-16-2012 |
| 20120064086 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 03-15-2012 |
| 20120076795 | Anti-PECAM Therapy, Compositions, Methods, and Uses - The disclosure relates to the discovery that systemic administration of an antibody that binds to PECAM-1 increases body weight while suppressing the metastatic spread of a wide variety of different tumor types which are typically fatal in humans. This discovery provides a basis for the generation of novel treatments and medicaments, wherein provision of a systemic dosage of anti-pECAM-1 antibody or a proxy that provides the same functional result is administered to a patient suffering from cancer cachexia and/or metastasis associated with end-stage cancer | 03-29-2012 |
| 20120121605 | ANTI SULFATIDES AND ANTI SUFATED PROTEOGLYCANS ANTIBODIES AND THEIR USE - The present invention relates to the biotechnology and particularly with new products for use in human health. | 05-17-2012 |
| 20120219559 | METHODS OF MODULATING IMMUNE FUNCTION - Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and/or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions. | 08-30-2012 |
| 20120269818 | METHODS FOR TREATING INFECTION BY HPV - We describe herein methods for treating HPV infections and medical conditions caused by HPV infections. Generally, the methods include administering to a subject exhibiting at least one symptom or clinical sign of HPV infection a composition that includes an EGFR signaling inhibitor in an amount effective to ameliorate the at least one symptom or clinical sign of HPV infection. | 10-25-2012 |
| 20130022613 | WISE/SOST NUCLEIC ACID SEQUENCES AND AMINO ACID SEQUENCES - The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways. | 01-24-2013 |
| 20130045212 | Biological Materials and Uses Thereof - There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C. There is also provided methods of identifying agents modulating tenascin-C and chronic inflammation. There are also provided uses of such agents. | 02-21-2013 |
| 20130095114 | T Cell Regulation - Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies. | 04-18-2013 |
| 20130142810 | USE OF THE COMBINATION OF SEMAPHORIN-4D INHIBITORY MOLECULES AND VEGF INHIBITORY MOLECULES TO INHIBIT ANGIOGENESIS - Provided herein are methods for inhibiting tumor angiogenesis in a cancer patient, the method comprising administering to the subject an effective amount of a first isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF. | 06-06-2013 |
| 20130156787 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS, AND METHOD FOR SCREENING FOR ACTIVE SUBSTANCES FOR PROMOTING ANGIOGENESIS - The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27. In addition, the present invention relates to a method for screening for active substances for promoting angiogenesis or for active substances for treating an angiogenesis-dependent ailment, the method comprising the following steps: treating vascular endothelial cell lines with each specimen; measuring the content of HSP27 in the respective vascular endothelial cell lines; and selecting a specimen in which the HSP27 content in the vascular endothelial cell lines are decreased as compared to a control group. | 06-20-2013 |
| 20130259872 | ANTI-ILT7- ANTIBODY - An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFNα. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFNα. | 10-03-2013 |
| 20130280270 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES - A method of treating an inflammatory disease in a subject in need thereof is carried out by administering the subject a gastrin-releasing peptide (GRP) inhibitor in a treatment effective amount. Suitable GRP inhibitors include compounds of the general formula: | 10-24-2013 |
| 20140030271 | HMGB1 SPECIFIC MONOCLONAL ANTIBODIES - The present invention concerns monoclonal antibodies specifically binding the human HMGB1 protein and further HMGB1 proteins of mammalian origin and also concerns fragments thereof, nucleic acids encoding such antibodies or fragments thereof, as well as vectors, cells, and compositions comprising the antibodies or nucleic acids, and uses thereof. | 01-30-2014 |
| 20140178400 | T-Helper Cell Type 17 Lineage-Specific Adjuvants, Compositions and Methods - The present invention relates to compositions and methods for modulation of T | 06-26-2014 |
| 20140199323 | Monoclonal Antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 07-17-2014 |
| 20140242089 | GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF - A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α | 08-28-2014 |
| 20140271662 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS - The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: | 09-18-2014 |
| 20140322229 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS - The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds. | 10-30-2014 |
| 20140328856 | TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G - The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg/kg to 800 mg/kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and/or an anti-beta amyloid monoclonal antibody. | 11-06-2014 |
| 20140348852 | METHOD FOR MAKING PRECIPITATED PARTICLES - The present invention relates to the provision of a novel method for preparing dry amorphous precipitated protein particles. In particular to a method provides amorphous precipitated protein particles suitable for use in dry protein formulations which can be reconstituted to provide clear, foam free concentrated protein solutions. | 11-27-2014 |
| 20150297591 | METHODS OF TREATING PULMONARY FIBROSIS - A method of treating ionizing radiation injury, or pulmonary fibrosis, or pulmonary hypertension due to any cause, such as idiopathic, autoimmune, or environmental, in a mammalian subject in need thereof, comprises administering the subject a gastrin-releasing peptide (GRP) blocking agent or inhibitor in a treatment effective amount. | 10-22-2015 |
| 20150301022 | METHODS FOR DETERMINING THE RISK OF ACUTE GRAFT VERSUS HOST DISEASE - The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed. | 10-22-2015 |
| 20150329918 | JAGGED1 AS A MARKER AND THERAPEUTIC TARGET FOR BREAST CANCER BONE METASTASIS - A method of treating Jagged1 induced bone metastasis is provided. A method of analyzing patients with tumors insensitive to RANK targeting treatments, but may respond to Jagged1 or Notch targeting therapies is provided. A method of treating patients with Jagged1 induced bone metastasis is provided. A method of predicting the therapeutic of treating a cancer patient with bone metastasis is provided. A kit for treating patients with Jagged1 induced bone metastasis is provided. A kit for predicting the therapeutic outcome of treating a cancer patient with bone metastasis using RANKL inhibitors is provided. | 11-19-2015 |
| 20150344567 | iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF - The present invention provides a monoclonal antibody that recognizes a lipid substance on an iPS cell surface and an ES cell surface as an epitope, and does not recognize EC cells, the antibody having a cytotoxic activity against a target cell, a method of producing a uniform differentiated cell population free of an undifferentiated cell, including contacting a cell population differentiated from an iPS or ES cell with the above antibody, and recovering viable cells, an agent for a cell transplantation therapy, containing a differentiated cell population obtained by the method, and the like. | 12-03-2015 |
| 20150344577 | AGENTS FOR TREATING TUMORS, USE AND METHOD THEREOF - The present disclosure provides agents for treating and/or preventing resistance of tumor cells to radiation therapy (RT), the use and relevant method thereof. | 12-03-2015 |
| 20150353623 | SUBSTANCES AND METHODS FOR THE TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY RELATED CONDITIONS OR DISEASES - A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient. | 12-10-2015 |
| 20160008440 | Use of CD83 in Combination Therapies | 01-14-2016 |
| 20160060329 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF LUNG CANCER - The present invention relates to methods and compositions for the detection of lung cancer. More particularly, the present invention provides monoclonal antibodies for the detection of lung cancer. | 03-03-2016 |
| 20160122422 | TREATMENT OF TAUOPATHIES - The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau. | 05-05-2016 |
| 20160201057 | SPARC (Secreted Protein, Acidic and Rich in Cysteine), A New Target for the Treatment and Prevention of Acute Liver Failure | 07-14-2016 |
| 20190144530 | TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G | 05-16-2019 |
